Everlab’s AU$65m Series A raises the stakes for preventive health platforms
Find out how Everlab’s AU$65m Series A could reshape AI preventive healthcare, diagnostics, patient data and scalable care access.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Can Pearl help Smile Brands turn dental radiographs into a system-wide care advantage?
Find out how Smile Brands’ Pearl dental AI rollout could reshape diagnostic consistency, patient trust and DSO adoption strategy.
Medical Devices & Diagnostics
Why Alcon’s Canadian UNITY CS launch matters beyond another cataract device rollout
Find out how Alcon’s UNITY CS launch in Canada could reshape cataract surgery workflows, adoption risks and medtech growth.
Pharma & Biotech
Why Biocytogen’s Boston accreditation matters for antibody discovery partners
Find out how Biocytogen’s AAALAC accreditation could strengthen preclinical research credibility and partner confidence.
Medical Devices & Diagnostics
Can SurGenTec’s ION-L system change how lumbar facet fixation fits into spine surgery?
Find out how SurGenTec’s ION-L FDA clearance could reshape minimally invasive lumbar facet fixation and spine surgery adoption.
Pharma & Biotech
Why Ascendis Pharma’s 182-week YORVIPATH data could matter for rare endocrine care
Find out how Ascendis Pharma’s YORVIPATH data could reshape hypoparathyroidism care and investor expectations.
Pharma & Biotech
Why EMA orphan status gives Zai Lab’s zoci more than a regulatory credibility boost
Find out how Zai Lab’s zocilurtatug pelitecan could reshape DLL3-targeted cancer therapy as development risks remain.
Pharma & Biotech
Could BMN 333 help BioMarin reset expectations in achondroplasia treatment?
Find out how BioMarin’s VOXZOGO and BMN 333 data could reshape rare bone disorder treatment as competition intensifies.
Pharma & Biotech
Edgewise Therapeutics’ Phase 2 HCM data put systolic function into sharper focus
Find out how Edgewise Therapeutics’ EDG-7500 data could reshape HCM drug development as Phase 3 questions emerge.
Pharma & Biotech
Why Lilly is betting on peripheral pain biology with the 4E Therapeutics acquisition
Find out how Lilly’s 4E Therapeutics deal could advance non-opioid chronic pain drugs and what risks remain.